Published in Nature on November 20, 1980
The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11. Biochem J (1984) 2.56
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Severe hypotension after first dose of enalapril in heart failure. Br Med J (Clin Res Ed) (1985) 2.14
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol (1982) 1.81
Autoradiographic visualization of angiotensin-converting enzyme in rat brain with [3H]captopril: localization to a striatonigral pathway. Proc Natl Acad Sci U S A (1984) 1.44
Tagged versus untagged libraries: methods for the generation and screening of combinatorial chemical libraries. Proc Natl Acad Sci U S A (1994) 1.40
Pharmacokinetics of enalapril in normal subjects and patients with renal impairment. Br J Clin Pharmacol (1986) 1.38
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev (2012) 1.31
Small molecule screen for compounds that affect vascular development in the zebrafish retina. Mech Dev (2009) 1.17
Converting enzyme inhibitors in hypertension and heart failure. Br Heart J (1983) 1.12
Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. Drugs (1985) 1.10
Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. Br J Clin Pharmacol (1984) 1.10
Tissue-specific expression of mRNAs for dipeptidyl carboxypeptidase isoenzymes. Proc Natl Acad Sci U S A (1982) 1.10
Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br Heart J (1983) 1.07
Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol (1985) 1.05
Enalapril: a review of human pharmacology. Drugs (1985) 1.02
Crystallographic studies on apocarboxypeptidase A and the complex with glycyl-L-tyrosine. Proc Natl Acad Sci U S A (1983) 1.00
Investigating the selectivity of metalloenzyme inhibitors. J Med Chem (2013) 0.99
Isolation of an angiotensin II-binding protein from liver. Proc Natl Acad Sci U S A (1984) 0.99
Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects. Br Med J (Clin Res Ed) (1981) 0.98
Phosphorus-containing inhibitors of angiotensin-converting enzyme. Proc Natl Acad Sci U S A (1982) 0.93
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov (2015) 0.93
An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol (1984) 0.91
Investigating endogenous peptides and peptidases using peptidomics. Biochemistry (2011) 0.91
Peptidomics approach to elucidate the proteolytic regulation of bioactive peptides. Proc Natl Acad Sci U S A (2012) 0.91
Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis. Br Med J (Clin Res Ed) (1982) 0.91
Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension. Br J Clin Pharmacol (1984) 0.90
Emerging trends in metalloprotein inhibition. Dalton Trans (2011) 0.89
Chemical ecology: a view from the pharmaceutical industry. Proc Natl Acad Sci U S A (1995) 0.89
Exploration of fluorine chemistry at the multidisciplinary interface of chemistry and biology. J Org Chem (2013) 0.87
Unexpected binding of an octapeptide to the angiotensin II receptor. Proc Natl Acad Sci U S A (1987) 0.87
Angiotensin-converting enzyme inhibition, but not AT(1) receptor blockade, in the solitary tract nucleus improves baroreflex sensitivity in anesthetized transgenic hypertensive (mRen2)27 rats. Hypertens Res (2011) 0.87
Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clin Exp Immunol (2000) 0.86
Endopeptidase 3.4.24.11 converts N-1-(R,S)carboxy-3-phenylpropyl-Ala-Ala-Phe-p-carboxyanilide into a potent inhibitor of angiotensin-converting enzyme. Biochem J (1993) 0.85
The behaviour of leucine aminopeptidase towards thionopeptides. Biochem J (1987) 0.83
RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers. Br J Clin Pharmacol (1981) 0.83
A peptidomics strategy to elucidate the proteolytic pathways that inactivate peptide hormones. Biochemistry (2011) 0.82
Interpretable correlation descriptors for quantitative structure-activity relationships. J Cheminform (2009) 0.81
The effect of enalapril (MK421), an angiotensin converting enzyme inhibitor, on the conscious pregnant ewe and her foetus. Br J Pharmacol (1986) 0.81
Congenital renal tubular dysplasia and skull ossification defects similar to teratogenic effects of angiotensin converting enzyme (ACE) inhibitors. J Med Genet (1997) 0.81
Prodrugs. Br J Clin Pharmacol (1989) 0.80
The chemistry of enalapril. Br J Clin Pharmacol (1984) 0.80
Effects of repeated doses of enalapril on renal function in man. Br J Clin Pharmacol (1985) 0.79
Impairment of granulomatous inflammatory response to Histoplasma capsulatum by inhibitors of angiotensin-converting enzyme. Infect Immun (1985) 0.78
Analysis of the proteolysis of bioactive peptides using a peptidomics approach. Nat Protoc (2013) 0.78
Sequential allylic C-H amination/vinylic C-H arylation: a strategy for unnatural amino acid synthesis from α-olefins. Org Lett (2012) 0.77
ACE for all - a molecular perspective. J Cell Commun Signal (2014) 0.77
New Frontiers in Druggability. J Med Chem (2015) 0.77
Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions--parallels and contrasts. Br J Clin Pharmacol (1987) 0.76
Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat. Drug Metab Dispos (2014) 0.76
Extrapolative prediction using physically-based QSAR. J Comput Aided Mol Des (2016) 0.75
Competitive inhibition of human skin collagenase by N-benzyloxycarbonyl-L-prolyl-L-alanyl-3-amino-2-oxopropyl-L-leucyl-L- alanylglycine ethyl ester. Biochem J (1986) 0.75
Inhibitor designing, virtual screening, and docking studies for methyltransferase: A potential target against dengue virus. J Pharm Bioallied Sci (2016) 0.75
Chemical design of cilazapril. Br J Clin Pharmacol (1989) 0.75
Inhibitor and substrate binding by angiotensin-converting enzyme: quantum mechanical/molecular mechanical molecular dynamics studies. J Chem Inf Model (2011) 0.75
A new high-resolution crystal structure of the Drosophila melanogaster angiotensin converting enzyme homologue, AnCE. FEBS Open Bio (2015) 0.75
Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet (1990) 7.04
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A (1980) 6.31
A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (1996) 5.45
Mutations in RPE65 cause Leber's congenital amaurosis. Nat Genet (1997) 4.48
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol (1980) 4.24
A single amino acid can determine the DNA binding specificity of homeodomain proteins. Cell (1989) 4.05
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem (2001) 3.69
Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol (2000) 3.61
Antibacterial agents that inhibit lipid A biosynthesis. Science (1996) 3.38
Two semi-automatic elutriators for extracting nematodes and certain fungi from soil. J Nematol (1976) 3.10
Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus. J Virol (1979) 2.94
Presence of haemagglutinin in the envelope of extracellular vaccinia virus particles. J Gen Virol (1976) 2.78
Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst (2001) 2.64
Avermectins, new family of potent anthelmintic agents: isolation and chromatographic properties. Antimicrob Agents Chemother (1979) 2.64
Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J Virol (1992) 2.60
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 2.49
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol (2000) 2.49
The paired box encodes a second DNA-binding domain in the paired homeo domain protein. Genes Dev (1991) 2.35
CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Curr Biol (1997) 2.35
Mechanism of vaccinia virus release and its specific inhibition by N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine. J Virol (1979) 2.33
A light and electron microscope study of long-term organized cultures of rat dorsal root ganglia. J Cell Biol (1967) 2.33
Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol (1998) 2.21
Application of molecular typing techniques in the 1998 dengue epidemic in Nicaragua. Am J Trop Med Hyg (1999) 2.20
Adsorption and penetration of enveloped and naked vaccinia virus particles. J Virol (1978) 2.06
Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. Nat Genet (1999) 2.04
Protein antigen-monoclonal antibody contact sites investigated by limited proteolysis of monoclonal antibody-bound antigen: protein "footprinting". Proc Natl Acad Sci U S A (1988) 2.03
Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J Virol (1996) 2.03
The mouse Engrailed-1 gene and ventral limb patterning. Nature (1996) 1.98
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med (2000) 1.94
Orphan G-protein-coupled receptors and natural ligand discovery. Trends Pharmacol Sci (2001) 1.94
A mutation in the gene encoding the vaccinia virus 37,000-M(r) protein confers resistance to an inhibitor of virus envelopment and release. J Virol (1991) 1.90
Selective inhibitors of biosynthesis of aminergic neurotransmitters. Nature (1978) 1.88
Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology (2001) 1.87
Phosphonomycin: structure and synthesis. Science (1969) 1.87
Fate mapping of the mouse midbrain-hindbrain constriction using a site-specific recombination system. Curr Biol (1998) 1.83
PCR detection and identification of Leishmania parasites in clinical specimens in Ecuador: a comparison with classical diagnostic methods. J Parasitol (1999) 1.80
The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab Dispos (1982) 1.79
Simplified polymerase chain reaction detection of new world Leishmania in clinical specimens of cutaneous leishmaniasis. Am J Trop Med Hyg (1998) 1.76
Emergent insights from the synthesis of conceptual frameworks for biological invasions. Ecol Lett (2011) 1.73
Notes on synaptic vesicles and related structures, endoplasmic reticulum, lysosomes and peroxisomes in nervous tissue and the adrenal medulla. J Histochem Cytochem (1973) 1.72
Allele-specific activation of genetically engineered receptors. J Biol Chem (1991) 1.72
Common HLA antigens in couples with repeated abortions. Clin Immunol Immunopathol (1977) 1.70
Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax (2003) 1.69
Conformationally restricted bicyclic analogs of somatostatin. Proc Natl Acad Sci U S A (1978) 1.69
Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. J Immunol (1998) 1.67
The transmission of refractive errors within eskimo families. Am J Optom Arch Am Acad Optom (1969) 1.66
Alpha-isopropylmalate synthase from yeast: purification, kinetic studies, and effect of ligands on stability. J Bacteriol (1972) 1.66
Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo. J Gen Virol (1985) 1.62
Uptake of protein by mammalian neurons. J Cell Biol (1969) 1.61
Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol (2000) 1.57
Risk factors associated with recent transmission of tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis (2009) 1.54
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J Med Chem (1993) 1.54
Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. J Immunol (1983) 1.53
A developmentally regulated microsomal protein specific for the pigment epithelium of the vertebrate retina. J Neurosci Res (1993) 1.45
Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther (1981) 1.44
The homeodomain: a new face for the helix-turn-helix? Bioessays (1992) 1.42
A potent cyclic hexapeptide analogue of somatostatin. Nature (1981) 1.42
Maternal and Infant Services: examination of access in a culturally diverse community. J Paediatr Child Health (2003) 1.42
The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem (1998) 1.42
Peptidomimetic regulation of growth hormone secretion. Endocr Rev (1997) 1.40
Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens (1995) 1.40
Receptor for motilin identified in the human gastrointestinal system. Science (1999) 1.39
A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science (1985) 1.39
Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422. Mol Pharmacol (1984) 1.38
Microtubule arrays in taxol-treated mouse dorsal root ganglion-spinal cord cultures. Brain Res (1981) 1.38
A role for Gbx2 in repression of Otx2 and positioning the mid/hindbrain organizer. Nature (1999) 1.37
Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (1998) 1.36
Pneumocandins from Zalerion arboricola. I. Discovery and isolation. J Antibiot (Tokyo) (1992) 1.35
Training senior house officers. BMJ (1997) 1.35
Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J Virol (1992) 1.34
Chemokines in acute anterior uveitis. Curr Eye Res (1997) 1.34
The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant (2008) 1.33
Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.32
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem (1996) 1.32
The reliability and validity of doctor-recorded morbidity data in active data collection systems. Scand J Prim Health Care (1998) 1.31
Anger regulation deficits in combat-related posttraumatic stress disorder. J Trauma Stress (1997) 1.30
Endocarditis in high-risk neonates. Pediatrics (1983) 1.29
High-frequency scrotal sonography. AJR Am J Roentgenol (1983) 1.29
Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J (1976) 1.28
HLA antigens in ulcerative colitis and Crohn's disease in Israel. Gastroenterology (1980) 1.28
The hypothermia of hypoglycemia. Studies with 2-deoxy-D-glucose in normal human subjects and mice. N Engl J Med (1972) 1.28
Population bottlenecks and patterns of human polymorphism. Mol Biol Evol (1999) 1.28
The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme. Adv Enzymol Relat Areas Mol Biol (1985) 1.27
A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog (1997) 1.27
An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res (1992) 1.26
Inhaled benzo(a)pyrene impairs long-term potentiation in the F1 generation rat dentate gyrus. Cell Mol Biol (Noisy-le-grand) (2004) 1.26
Potentiation of adrenergic venomotor responses by angiotensin, prostaglandin F 2 and cocaine. J Pharmacol Exp Ther (1971) 1.26